SanBio

San Bio

Biotechnology, 231 South Whisman Rd, Mountain View, California, United States, 11-50 Employees

sanbio.com/en

  • LinkedIn

Who is SANBIO

Founded in February 2001 SanBio's scope of business is development, production and sales of regenerative cell medicines. Our mission is to develop regenerative medicines, creating benefit...

Read More

map
  • 231 South Whisman Rd, Mountain View, California, United States Headquarters: 231 South Whisman Rd, Mountain View, California, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $25 Million to $50 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 5122

checked-icon Does something look wrong? Fix it. | View contact records from SANBIO

SanBio Org Chart and Mapping

Employees

Thang Tran

Executive Director, Quality Assurance

Chris Sim

Head of Information Technology

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding SanBio

Answer: SanBio's headquarters are located at 231 South Whisman Rd, Mountain View, California, United States

Answer: SanBio's official website is https://sanbio.com/en

Answer: SanBio's revenue is $25 Million to $50 Million

Answer: SanBio's SIC: 5122

Answer: SanBio has 11-50 employees

Answer: SanBio is in Biotechnology

Answer: SanBio contact info: Phone number: Website: https://sanbio.com/en

Answer: Founded in February 2001 SanBio's scope of business is development, production and sales of regenerative cell medicines. Our mission is to develop regenerative medicines, creating benefits for patients and value for stakeholders. Our vision is to achieve global leadership in the regenerative medicine field using best science and technology, building global revenues and sponsoring successful clinical trials. SanBio focuses on using regenerative cell medicine to treat the disabilies caused by diseases of the central nervous system. Most of these conditions currently have no effective medicinal treatment, and those treatment that do exist generally address disease symptoms and not the underlying cause of the disease. Such conditions afflict a vast number of patients worldwide.As of January, 2016, SanBio had introduced a product for the treatment of chronic motor impairment from ischemic stroke and traumatic brain injury into clinical development in both Japan and the US. In the future, SanBio plans to continue expanding the indications and geographical regions for its products, using both internal development, as well as partnerships and licenses.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access